Steve Elms sold $8.8M of ADMA Biologics (ADMA)

Executed Jun 12 2025, disclosed Jun 16 2025, 4 days later.

Value, as filed

$8.8M

425,621 sh across 3 lots

Executed

Jun 12 2025

the trade date, as filed

Disclosed

Jun 16 2025

4 days after the trade

Return, 21 sessionsiFrom the disclosed entry session; derived

–

purchases only

Returns are measured on stock purchases only.

The filer

Steve Elms Director profile →

Steve Elms (Director) filed 1 Form 4 report in the trailing twelve months (1 purchase, 0 sales), most often in ADMA Biologics, Inc. (ADMA). Across 1 priced purchase filing, the average 21-session return was -44.2% from execution and -40.9% from disclosure (delay-adjusted; derived). The largest single filing was $217K of ADMA (14,000 sh across 2 lots, as filed), executed Mar 5.

The name

ADMA

ADMA Biologics, Inc. ADMA · Healthcare · 23 filings in 24 months ticker →

Healthcare · ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment…

More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→

Other filings by Steve Elms in ADMA

ADMAPURCHASE ADMA Biologics, Inc. $217K
14,000 sh across 2 lots
Exec Mar 5
Filed Mar 9 · 9:14 AM ET